277 related articles for article (PubMed ID: 28844141)
1. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
Brand S; Ko EJ; Viayna E; Thompson S; Spinks D; Thomas M; Sandberg L; Francisco AF; Jayawardhana S; Smith VC; Jansen C; De Rycker M; Thomas J; MacLean L; Osuna-Cabello M; Riley J; Scullion P; Stojanovski L; Simeons FRC; Epemolu O; Shishikura Y; Crouch SD; Bakshi TS; Nixon CJ; Reid IH; Hill AP; Underwood TZ; Hindley SJ; Robinson SA; Kelly JM; Fiandor JM; Wyatt PG; Marco M; Miles TJ; Read KD; Gilbert IH
J Med Chem; 2017 Sep; 60(17):7284-7299. PubMed ID: 28844141
[TBL] [Abstract][Full Text] [Related]
2. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
[TBL] [Abstract][Full Text] [Related]
3. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
Benaim G; Sanders JM; Garcia-Marchán Y; Colina C; Lira R; Caldera AR; Payares G; Sanoja C; Burgos JM; Leon-Rossell A; Concepcion JL; Schijman AG; Levin M; Oldfield E; Urbina JA
J Med Chem; 2006 Feb; 49(3):892-9. PubMed ID: 16451055
[TBL] [Abstract][Full Text] [Related]
4. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
[TBL] [Abstract][Full Text] [Related]
5. Cure of short- and long-term experimental Chagas' disease using D0870.
Urbina JA; Payares G; Molina J; Sanoja C; Liendo A; Lazardi K; Piras MM; Piras R; Perez N; Wincker P; Ryley JF
Science; 1996 Aug; 273(5277):969-71. PubMed ID: 8688084
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Optimization of a Compound Series Active against
Harrison JR; Sarkar S; Hampton S; Riley J; Stojanovski L; Sahlberg C; Appelqvist P; Erath J; Mathan V; Rodriguez A; Kaiser M; Pacanowska DG; Read KD; Johansson NG; Gilbert IH
J Med Chem; 2020 Mar; 63(6):3066-3089. PubMed ID: 32134269
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi.
Molina J; Brener Z; Romanha AJ; Urbina JA
J Antimicrob Chemother; 2000 Jul; 46(1):137-40. PubMed ID: 10882704
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi.
da Silva CF; Batista MM; Batista Dda G; de Souza EM; da Silva PB; de Oliveira GM; Meuser AS; Shareef AR; Boykin DW; Soeiro Mde N
Antimicrob Agents Chemother; 2008 Sep; 52(9):3307-14. PubMed ID: 18625779
[TBL] [Abstract][Full Text] [Related]
9. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
[TBL] [Abstract][Full Text] [Related]
10. Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against
Lara LS; Lechuga GC; Moreira CDS; Santos TB; Ferreira VF; da Rocha DR; Pereira MCS
Molecules; 2021 Jan; 26(2):. PubMed ID: 33467422
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
[TBL] [Abstract][Full Text] [Related]
12. Novel Diarylthioether Compounds as Agents for the Treatment of Chagas Disease.
Beveridge J; Tran E; Deora GS; Huang F; Wang Y; Stockton K; Cotillo I; Martinez Martinez MS; Gonzalez S; Castañeda P; Sherman J; Rodriguez A; Kessler A; Baell JB
J Med Chem; 2023 Jan; 66(2):1522-1542. PubMed ID: 36626662
[TBL] [Abstract][Full Text] [Related]
13. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, Design, and Structure-Activity Relationship of a Benzenesulfonylpiperazine Series against Trypanosoma cruzi.
Cassiano Martinho AC; de Melo Resende D; Landin ES; Dit Lapierre TJWJ; Bernardes TCD; Martins LC; Ferreira RS; Murta SMF; de Oliveira Rezende Júnior C
ChemMedChem; 2022 Oct; 17(19):e202200211. PubMed ID: 35993440
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
[TBL] [Abstract][Full Text] [Related]
16. Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-chagas agents.
Muscia GC; Roldán Pacheco FJ; Asís SE; Buldain GY; Frank FM
Eur J Med Chem; 2020 Jan; 186():111877. PubMed ID: 31771829
[TBL] [Abstract][Full Text] [Related]
17. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.
Monteiro ME; Lechuga G; Lara LS; Souto BA; Viganó MG; Bourguignon SC; Calvet CM; Oliveira FOR; Alves CR; Souza-Silva F; Santos MS; Pereira MCS
Eur J Med Chem; 2019 Nov; 182():111610. PubMed ID: 31434040
[TBL] [Abstract][Full Text] [Related]
19. Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Ashworth R; Wilkinson SR; Kaiser M; Andriani G; Rodriguez A
Future Med Chem; 2013 Oct; 5(15):1763-76. PubMed ID: 24144412
[TBL] [Abstract][Full Text] [Related]
20. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
MacLean LM; Thomas J; Lewis MD; Cotillo I; Gray DW; De Rycker M
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006612. PubMed ID: 30001347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
